Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIKTIMVO vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction.,To slow the progression of diabetic kidney disease in adults with type 2 diabetes and chronic kidney disease.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life: 18 hours (range 14-22 hours), supporting once-daily dosing.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
NIKTIMVO is primarily metabolized via glucuronidation by UGT1A9, with minor metabolism via CYP3A4.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion: 70% as unchanged drug; fecal elimination: 30% as metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution (e.g., liver, kidney).
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 85% with food; IV: 100%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (Cr Cl <30 m L/min) has not been studied; use with caution.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not studied; use with caution.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For patients aged 12 years and older: same as adult dosing. For children <12 years: not recommended due to lack of data.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment required; efficacy and safety similar to younger adults; monitor for immune-related adverse events more closely.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
There is no black box warning for NIKTIMVO.
None.
Ketoacidosis, including life-threatening cases, in patients with type 1 or type 2 diabetes.,Volume depletion, hypotension, and acute kidney injury, especially in patients with impaired renal function or on diuretics.,Urosepsis and pyelonephritis.,Hypoglycemia when used with insulin or insulin secretagogues.,Necrotizing fasciitis of the perineum (Fournier gangrene).
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.,History of serious hypersensitivity reaction to NIKTIMVO.,Concomitant use with other SGLT2 inhibitors.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions have been established. However, patients should maintain a balanced diet and avoid grapefruit and other known CYP3A4 inhibitors if concomitant medications that are metabolized by CYP3A4 are used. No dietary restrictions required solely for NIKTIMVO.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk cannot be excluded. Use only if benefit outweighs risk. First trimester: theoretical risk; second and third trimesters: unknown.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Unknown if excreted in human milk. No M/P ratio available. Due to potential for adverse reactions in breastfed infants, advise against breastfeeding during treatment and for at least 5 half-lives after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. However, physiological changes in pregnancy may alter exposure; monitor for efficacy and toxicity.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
NIKTIMVO (nivolumab) is an immune checkpoint inhibitor targeting PD-1. Monitor for immune-related adverse events (ir AEs), especially pneumonitis, colitis, hepatitis, and endocrinopathies. Infusion reactions may occur; premedicate with antihistamines and acetaminophen if indicated. Avoid use in patients with active autoimmune disease or those requiring chronic immunosuppression. Assess baseline liver, renal, and thyroid function before initiation.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Report any new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, jaundice, rash, or thyroid dysfunction signs (e.g., fatigue, weight changes).,Do not receive live vaccines during treatment and for at least 1 month after last dose.,Inform your doctor of all medications, including over-the-counter drugs, especially immunosuppressants or corticosteroids.,Use effective contraception during treatment and for at least 5 months after the last dose.,Notify your doctor immediately if you experience symptoms of infusion reactions (fever, chills, itching, dizziness).
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIKTIMVO vs AURLUMYN, answered by our medical review team.
NIKTIMVO is a Antineoplastic agent that works by NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIKTIMVO and AURLUMYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIKTIMVO is: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIKTIMVO and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIKTIMVO is classified as Category C. Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk canno. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.